high mobility group box 1  (Cusabio)

Journal: BMC Veterinary Research

Article Title: Dietary capsaicin supplementation attenuates jejunal injury of piglets challenged with lipopolysaccharide

doi: 10.1186/s12917-026-05346-6

Figure Lengend Snippet: Effect of dietary CAP supplementation on necroptosis of epithelial cells in the jejunum of LPS-challenged piglets. A The mRNA expression of RIPK1 , RIPK3 , MLKL , and PGAM5 in the jejunum ( n = 8). B , C Representative immunohistochemistry results and quantitative analysis of HMGB1 protein in the jejunum (scale bar = 100 μm; n = 6). Cells exhibiting yellow-brown staining were considered HMGB1-positive. CON, piglets fed a basal diet; LPS, LPS-challenged piglets fed a basal diet; LCA, LPS-challenged piglets fed a basal diet with 800 mg/kg CAP. a−c Different letters among groups were considered as statistical significance ( P < 0.05). The results were emerged as mean and SEM. RIPK1 Receptor-interacting protein kinase 1, RIPK3 Receptor-interacting protein kinase 3, MLKL Mixed lineage kinase domain like pseudokinase, PGAM5 Phosphoglycerate mutase family member 5, HMGB1 High mobility group box 1

Article Snippet: Subsequently, 3% bovine serum albumin was used to block the slides for 30 min at room temperature, and the jejunal sections were incubated with the primary antibody against integrin alpha M (CD11b; #GB11058-100; Servicebio Technology) and high mobility group box 1 (HMGB1; #GB11103-100; Servicebio Technology) in a wet box overnight at 4 °C.

Techniques: Expressing, Immunohistochemistry, Staining

Journal: Journal of Nanobiotechnology

Article Title: HIFU postoperative hypoxia-activated metal-organic frameworks modulate the tumor microenvironment to augment immunotherapy

doi: 10.1186/s12951-026-04079-w

Figure Lengend Snippet: Study on antitumor mechanisms in vitro. ( a - d ) CRT, HMGB1 and ATP release of 4T1 cells following treatment with free AQ4N and AFNC MOFs for 48 h under normoxic or hypoxic conditions. Scale bar: 25 μm, 50 μm. ( e ) and ( f ) Intracellular Ca 2+ uptake. ( g ) In vitro lactate depletion capacity of AFNC MOFs. ( h ) Kyn inhibition rates of 4T1 cells treated with free NLG919 and AFNC MOFs for 24 h. I: PBS; II: AQ4N with normoxic; III*: AFN MOFs with normoxic; III: AFNC MOFs with normoxic; IV: AQ4N with hypoxic conditions; V: AFNC MOFs with hypoxic conditions. (Mean ± SD, n = 3, ** p < 0.01, *** p < 0.001, **** p < 0.0001, represent significant difference.)

Article Snippet: Proliferating cell nuclear antigen (PCNA) antibody, calreticulin (CRT) antibody and high mobility group box 1 (HMGB1) antibody were purchased from Novus Biologicals (USA).

Techniques: In Vitro, Inhibition

Journal: Journal of Nanobiotechnology

Article Title: HIFU postoperative hypoxia-activated metal-organic frameworks modulate the tumor microenvironment to augment immunotherapy

doi: 10.1186/s12951-026-04079-w

Figure Lengend Snippet: AFNC MOFs mediated TME immunomodulation of 4T1 tumor. ( a - c ) Representative immunofluorescence images of CRT exposure and HMGB1 release of tumor tissues following various treatments. Scale bar = 100 μm. ( d ) Quantitative analyses of lactic acid (LAC) consumption in tumor. ( e ) Western blot of the relative expression of associated proteins within 4T1 tumor tissues following various treatments (internal reference: Tubulin) ( n = 3). ( f - q ) Quantitative analyses of DCs (CD80 + CD86 + ), CD8 + T cells (CD3 + CD8 + ), Tregs (CD25 + Foxp3 + ), M1-like and M2-like TAMs (F4/80 + CD206 + ) in tumors after different treatments ( n = 3). I: PBS; II: AQ4N; III: AF MOFs; IV: HIFU; V: AF MOFs+HIFU; VI: AFN MOFs+HIFU; VII: AFNC MOFs+HIFU. (Mean ± SD, n = 3; ns, not statistically significant; ** p < 0.01, *** p < 0.001, **** p < 0.0001, represent significant difference.) ( r ) Intra-tumoral Kyn/Trp ratio examined from various treatment groups ( n = 3). ( s ) Tumor volume curves after re-inoculation with tumor cells ( n = 5)

Article Snippet: Proliferating cell nuclear antigen (PCNA) antibody, calreticulin (CRT) antibody and high mobility group box 1 (HMGB1) antibody were purchased from Novus Biologicals (USA).

Techniques: Immunofluorescence, Western Blot, Expressing